GLP-1s in Perimenopause and Menopause: What the Evidence Shows

The short answer

Menopause can be part of a weight-care conversation, but it is not evidence that everyone in midlife needs a GLP-1. Research specifically examining menopause and these medicines is narrower than the broad obesity literature. A frequently cited semaglutide study found an association between hormone therapy use and greater weight loss; it did not prove that adding hormones improves a GLP-1's effect.¹

The most useful appointment separates three concerns: weight-related health, menopause symptoms and day-to-day function. A prescription that addresses one concern should not be presented as a proven solution for all three.

What the semaglutide study actually found

The 2024 study followed records of 106 postmenopausal women using semaglutide for overweight or obesity. Sixteen used menopause hormone therapy and 90 did not. At 12 months, the reported mean weight reduction was 16% in the hormone-therapy group and 12% in the other group. The association persisted after statistical adjustment.¹

This was a retrospective cohort, not a trial randomly assigning hormone therapy. The small hormone-treatment group and differences between patients limit causal interpretation. The result is a reason to investigate further, not a forecast of your weight loss or a reason to start hormone therapy for additional weight reduction. It also cannot directly answer the same question for perimenopause or for every GLP-1 medicine.

Why the scale is not the whole midlife question

The longitudinal Study of Women's Health Across the Nation examined body composition across the menopause transition. It reported changes in fat and lean mass that were not captured simply by assuming a new acceleration in body-weight gain. That distinction matters when interpreting a stable scale alongside changes in waist size or physical function.²

It does not mean you can diagnose the cause of a body change from a photograph or a waist measurement. It does mean an appointment can be more useful when you bring specific concerns. “I want to discuss my changing waist size and whether my health risks have changed” gives your clinician more to work with than “my hormones are broken.”

Ask how progress will be assessed beyond weight. Possible discussion points include strength, energy, nutrition, sleep and the health condition for which treatment is being considered. Your clinician can decide which measurements and investigations are appropriate; a consumer checklist cannot choose those for you.

Bring two lists to the appointment

On the first, write the symptoms or health concerns you want addressed: for example, disrupted sleep, bothersome hot flashes, reduced exercise tolerance or weight-related limitations. On the second, list medicines and supplements, previous weight treatments, side effects and what made a prior plan hard to sustain.

Keep the lists separate so an improvement in one area does not hide an unresolved problem elsewhere. If appetite changes while sleep remains poor, you still need a plan for the sleep concern. If a program sells weight treatment and menopause care together, ask who assesses each problem and whether the fees cover both services.

Useful questions include:

• What diagnosis or health goal would this medication address for me?
• Which symptoms need their own evaluation rather than being attributed to weight?
• What evidence supports the proposed treatment in someone with my history?
• Who will coordinate care if I already have a menopause clinician?
• How will we monitor eating, physical function and tolerability?
• What would make us reconsider the treatment or its pace?

These questions are especially valuable when the consultation is brief. Send them ahead if the clinic accepts secure messages, and keep your own copy of the answers.

Be cautious with the “hormone reset” sales pitch

A study comparing people who happened to use different treatments is not proof of a package sold by a clinic. Ask a provider to identify the specific study behind a claim and whether it measured the outcome being promised. Weight loss, hot-flash relief, improved sleep and preservation of muscle are different outcomes.

Similarly, a testimonial is not a controlled comparison. Someone may be pleased with a program while still having changed several things at once. The semaglutide findings above should not be turned into a guaranteed four-percentage-point bonus for buying another prescription.

For practical follow-up, use our muscle-preservation guide to prepare questions about activity and nutrition, and our fatigue guide if energy is a concern. The Midi review examines a menopause-focused care option; it is a service review, not evidence that a particular treatment is appropriate for you.